Pacritinib for relapsed or refractory Waldenström macroglobulinemia
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have Waldenström macroglobulinemia that is causing symptoms or lab problems like fever, night sweats, fatigue, low blood counts, enlarged lymph nodes, or kidney issues.
- You have tried at least 2 prior treatments, and you have either used a BTK inhibitor (a type of targeted therapy) or your doctor says you cannot take one.
- Your blood counts and organ function (kidney, liver) meet specific levels, such as adequate neutrophils, platelets, and kidney function.
- You are not pregnant, breastfeeding, or planning to become pregnant during and for 3 months after the study. If you can become pregnant, you must use two forms of birth control or remain abstinent.
- You do not have uncontrolled infections, active hepatitis B or C, uncontrolled HIV, significant heart problems, or an inability to swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
This trial tests epcoritamab, an immunotherapy that helps your immune system attack cancer cells, for people with Waldenstrom macroglobulinemia (WM) whose disease has gotten worse or who couldn't tolerate previous treatments. It's for those who've already tried a BTK inhibitor (like ibrutinib or zanubrutinib) and an anti-CD20 antibody (like rituximab).
This study tests a new drug called teclistamab for people with Waldenstrom's macroglobulinemia (WM) that has come back or not responded to earlier treatments. The drug is designed to help your immune system attack the cancer cells. The study aims to see if it is safe and effective.
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
This trial tests a combination of two drugs—mosunetuzumab and pirtobrutinib—in patients whose Waldenstrom macroglobulinemia (a rare blood cancer) has returned or stopped responding to prior treatment. The study aims to see if this combination can shrink tumors and help patients feel better.
This trial tests a new combination of two targeted drugs (pacritinib plus a BTK inhibitor like ibrutinib) for people with mantle cell lymphoma that has come back or stopped responding to treatment. It may help if your current BTK inhibitor is no longer working well.
Hear when a new Waldenström Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.